BMC Cancer Oncology

PReCedeNT trial: Phase III randomized-controlled trial of Lutetium − 177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) plus Chemotherapy versus PRRT alone in FDG-avid, Well-differentiated Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Ameya D. Puranik, Indraja D. Dev, Sushil Yadav, Venkatesh Rangarajan, Archi Agrawal, Sandip Basu, Vikram A. Chaudhari, Anant Ramaswamy, Vikas Ostwal, Manish S. Bhandare, Shailesh V. Shrikhande, Rahul V. Parghane, Prabhat Bhargava, Munita M. Bal, Subhash Yadav, Shraddha Patkar, Mahesh Goel, Nilendu C. Purandare, Sneha Shah, Sayak Choudhury, Suchismita Ghosh, Manikandan Venkatachalam
Springer Nature · 2025-10-28 · DOI 10.1186/s12885-025-15111-x

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →